string(4) "4811"

HIV1/2 - Human Immunodeficiency Virus - screening serology - serum

Back to main menu

Eurofins Biomnis code

HIV

Synonyms

  • HIV-1/2 - screening control serology
  • ;

Clinic significance

Lentivirus (Retroviridae), responsible for AIDS. The infection leads to a major immune deficit related to gradual destruction of the population of CD4+ lymphocytes, thereby predisposing to opportunistic and tumour infections. We differentiate two kinds of virus antigens, HIV-1 and HIV-2. HIV-1 is the most common. Most strains belong to the M group, inside of which we differentiate at least 10 subtypes or recombinants (A to J). HIV-2 is subtype A of HIV-1 found particularly in Africa.
According to the Decree of 28 May 2010, French legislation stipulates since 1 October 2010, the use of a single combined HIV Elisa test (anti-HIV antibody and p24 antigen), CE label, with a detection threshold for p24 antigen at least equal to the minimal threshold required by European regulations of 2 IU/mL (WHO panel NIBSC 90/636). If this test is positive, a confirmation test (Western blot or immunoblot) is always initiated by the medical biologist on the same sample to identify the specificity of anti-HIV antibodies present in this initial serum. In case of a dubious negative result of the confirmation test and also at the request of the medical biologist, the assay of p24 antigen or a viral load test may be performed. In case of a positive confirmation test, the existence of anti-HIV-1/HIV-2 antibodies or p24 antigens in an individual, is only validated after the screening test performed on a second sample.

Prenalytics

  • 1 mL
  • Serum
  • Refrigerated

Further information

  • Storage temperature (2-8°C) < 7 days during transport of specimen.

Methodology

Chemiluminescence

Turnaround time

3 days


Pathologist(s) in charge
Biomnis Paris
Specialty
Infectious
Contact(s)
Dr Catherine COIGNARD
Dr Anne EBEL
Phone(s)
+331 49 59 63 37
+331 49 59 63 42